Companies · Other Health Care

General Fluidics Corp

WALTHAM · Other Health Care

Diligence memoA one-page analyst read on General Fluidics Corp — recommendation, valuation, rhythm, risks.
$34.6M
Total raised · real
4
Rounds
4.5×
Latest step-up
Top 11%
Sector rank · raised
Series B
Latest stage · inferred · Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

General Fluidics Corp looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.78× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
  • Within the normal band (78% of peer median) for its niche.
Quiet
  • Last raise 24 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

General Fluidics Corp is one of 5377 Other Health Care companies tracked from WALTHAM. By capital raised it ranks among the largest (ahead of 90% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
16
Investors (latest)
2024-07-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2018-09-24 Raised $5.4M (real) Modeled valuation $109M (est)$5.4M$109MSeries A2018Series A · 2020-12-09 Raised $6.7M (real) Modeled valuation $115M (est)$6.7M$115MSeries A2020Series A · 2022-06-29 Raised $8.3M (real) Modeled valuation $83M (est)$8.3M$83MSeries A2022Series A · 2022-06-30 Raised $4.1M (real) Modeled valuation $40M (est)$4.1M$40MSeries A2022Series B · 2024-07-16 Raised $18M (real) Modeled valuation $119M (est)$18M$119MSeries B2024+$6.7M+$8.3M+$4.1M+$18MCumulative $43M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$5.4M · 2018
Series A extension$6.7M · 2020
Series A extension$8.3M · 2022
Series A extension$4.1M · 2022
Series B$18.5M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$119.4M
Base estimate est.
$43.4M
Conservative case
$212.1M
Upside case
$102.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $108.5M · 2018-09-242018Series A · modeled $114.6M · 2020-12-09Series A · modeled $82.5M · 2022-06-29Series A · modeled $40.5M · 2022-06-30Series B · modeled $119.4M · 2024-07-162024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
2.0 yr
Elapsed time used
2.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
17 mo
Avg between rounds
$6.0M/yr
Capital velocity
7.8 yr
On record since
2018
First round
5
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 14× above median
This company$34.6M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.0× above median
This company$18.5M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 5.4× above median
This company$119.4M
Sector median$22.1M

Raised more than 90% of sector peers (real $). Modeled value above 82% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #61 of 91.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Code Biotherapeutics, Inc. · Series B Raised $47.5M · modeled $465.8M (est)Candesant Biomedical, Inc. · Series B Raised $44.5M · modeled $455.3M (est)Artis Holdings, LLC · Series B Raised $40.0M · modeled $383.5M (est)GIO Blood Ltd · Series B Raised $27.3M · modeled $375.5M (est)Clarapath, Inc. · Series B Raised $40.2M · modeled $348.4M (est)Diality Inc · Series B Raised $42.9M · modeled $337.7M (est)VA Pro 7 SNF Operations Holdings LLC · Series B Raised $32.0M · modeled $333.3M (est)VivoSense, Inc. · Series B Raised $27.0M · modeled $332.6M (est)Tidal Wave GPO, LLC · Series B Raised $34.8M · modeled $324.6M (est)Peachy Corp. · Series B Raised $25.1M · modeled $309.9M (est)Smile Source Holdings, L.P. · Series B Raised $32.2M · modeled $309.0M (est)ASC San Rafael LLC · Series B Raised $28.3M · modeled $295.1M (est)General Fluidics Corp (this company) Raised $34.6M · modeled $119.4M (est)General Fluidics Corp
CompanyStageRaised · realValue · estvs peer med.
Code Biotherapeutics, Inc.Series B$47.5M$465.8M3.06×
Candesant Biomedical, Inc.Series B$44.5M$455.3M2.99×
Artis Holdings, LLCSeries B$40.0M$383.5M2.52×
GIO Blood LtdSeries B$27.3M$375.5M2.47×
Clarapath, Inc.Series B$40.2M$348.4M2.29×
Diality IncSeries B$42.9M$337.7M2.22×
VA Pro 7 SNF Operations Holdings LLCSeries B$32.0M$333.3M2.19×
VivoSense, Inc.Series B$27.0M$332.6M2.19×
Tidal Wave GPO, LLCSeries B$34.8M$324.6M2.13×
Peachy Corp.Series B$25.1M$309.9M2.04×
Smile Source Holdings, L.P.Series B$32.2M$309.0M2.03×
ASC San Rafael LLCSeries B$28.3M$295.1M1.94×
General Fluidics Corp this companySeries B$34.6M$119.4M0.78×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$5.4M2018-09-24$24.4M$108.5M90%
Series A$6.7M2020-12-09$30.2M$114.6M90%
Series A$8.3M2022-06-29$38.0M$82.5M90%
Series A$4.1M2022-06-30$18.6M$40.5M90%
Series B$18.5M2024-07-16$102.7M$119.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$5.4M2018-09-24
    • First recorded raise — entered as Series A.
    • 2 investors on this round.
  2. Series A$6.7M2020-12-09
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  3. Series A$8.3M2022-06-29
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Series A$4.1M2022-06-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  5. Series B$18.5M2024-07-16
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 4.5× larger than the prior — scaling up.
    • 16 investors on this round.
Intelligence
2025 ~Q4
Modeled next raise · ~17mo cadence
$55.5M
Modeled next size est.range $36.0M$88.7M
4.5×
Last step-up
$6.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Marc Goldberg8 other2024-07
Keith Greenfield2 other2020-12
Robert Warren1 other2022-06
RONALD TOMPKINS1 other2018-09
Christopher Sveen2020-12
Jason Napolitano2018-09
Nancy Gagliano2022-06
Ramin Haghgooie2022-06
Robert Granier2018-09
Timothy Hirsch2024-07
Registry & provenance

General Fluidics Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1755195
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cerebral Inc.Other Health CareSeries B$25.0M$117.4Mnetwork1 shared operator · same sector · same stage
Optimal IMX, Inc.Other Health CareSeries B$34.6M$99.7Msame sector · same stage
Firm Of John Dickinson Schneider IncOther Health CareSeries B$34.2M$144.8Msame sector · same stage
GHR Acquisition, LLCOther Health CareSeries B$35.3M$123.9Msame sector · same stage
HomeThrive, Inc.Other Health CareSeries B$35.3M$131.9Msame sector · same stage
STX Healthcare Management Services, Inc.Other Health CareSeries B$35.7M$128.2Msame sector · same stage
Myra Vision, Inc.Other Health CareSeries B$36.0M$108.8Msame sector · same stage
ZT Sapphire Fund I, L.P.Other Health CareSeries B$33.0M$117.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Functional Fluidics Inc.Other Health CareSeed$84.2M91%
BioMedx Group, Inc.Other Health CarePre-Seed$14.0M84%
HeartFlow Holding, Inc.Other Health CareSeries D+$432.6M84%
Medrobotics CorpOther Health CareSeries B$443.1M84%
Grande Delta CorpOther Health CareSeed$14.6M83%
Glyscend, Inc.Other Health CareSeries A$96.9M83%
BioCytics, Inc.Other Health CareSeed$11.0M83%
Premier Biomedical IncOther Health CareSeed$3.7M83%
Frequently asked
How much funding has General Fluidics Corp raised?
General Fluidics Corp has raised approximately $34.6M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is General Fluidics Corp's estimated valuation?
Provath's modeled valuation for General Fluidics Corp is approximately $119.4M (modeled range $43.4M–$212.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is General Fluidics Corp at?
General Fluidics Corp's latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Jul 16.
What does General Fluidics Corp do and where is it based?
General Fluidics Corp operates in the Other Health Care sector, based in WALTHAM.
Explore related

See where General Fluidics Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at General Fluidics Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.